Acute graft-versus-host disease (GVHD) is the major treatment-related complication after stemcell transplantation (SCT) from unrelated-donors. Several GVHD prophylaxis regimens have been explored, but no regimen has shown superiority. We analyzed transplantation outcomes in 472 consecutive unrelated-donor SCT recipients, using cyclosporine/methotrexate (MTX, n 5 314) or cyclosporine/mycophenolate-mofetil (MMF, n 5 158) for GVHD prophylaxis. Neutrophil engraftment was faster after MMF, days 11 and 14, respectively (P 5 .001). Acute GVHD grade II-IV and III-IV occurred in 47% and 28% after MMF compared to 27% and 12% after MTX, respectively (P < .001). Nonrelapse mortality (NRM) was 44% and 24%, respectively (P < .001). Death associated with GVHD occurred in 25% and 8% (P < .0001), while other NRM causes occurred in 19% and 16%, respectively (P 5 .39). Relapse mortality was similar. Overall survival was better after MTX, 40% and 29%, respectively (P 5 .006). However, this difference had only borderline significance when adjusting for differences in patient characteristics (HR, 1.3, P 5 .08). To minimize potential selection bias we analyzed outcomes on the basis of an intention-to-treat like analysis.
risk of increased toxicity. MTX doses are often omitted which may jeopardize efficacy. 7 There is therefore an interest in safer MTX-free regimens provided that GVHD prevention will not be inferior.
Mycophenolate mofetil (MMF) is an ester prodrug of the active immune suppressive agent mycophenolic acid (MPA). It is rapidly hydrolyzed after oral ingestion to the active metabolite. MPA is a selective inhibitor of inosine monophosphate dehydrogenase (IMPDH), a key enzyme and limiting step in the de novo purine biosynthesis. 8 It selectively targets activated lymphocytes which are dependent on this pathway. The combination of cyclosporine A (CsA) and MMF was developed in the canine model for nonmyeloablative transplantation. It has become a common regimen for GVHD prophylaxis especially in the nonmyeloablative setting. 10 Several studies have compared the outcome following calcineurin inhibitor with MTX or MMF with conflicting results. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] In this study,
we analyzed transplantation outcomes of 472 consecutive patients after SCT from unrelated donors using cyclosporine A (CsA) with MTX or MMF. We show that CsA/MTX prevents acute GVHD better but is relatively more toxic. It should remain the standard of care regimen for GVHD prophylaxis after unrelated donor transplants, but CsA/MMF may be considered in patients with comorbidities and a high risk for NRM.
| P A T I E NT S A ND M E T H O DS

| Patient eligibility
This retrospective study included all patients who were given allogeneic SCT from unrelated donors, in the Chaim Sheba Medical Center, over the years [2003] [2004] [2005] [2006] [2007] [2008] [2009] [2010] [2011] [2012] [2013] [2014] . Patients were eligible for allogeneic SCT based on standard hematological criteria. Only patients given cyclosporine with either MTX or MMF for GVHD prophylaxis were included.
Other GVHD prophylaxis regimens such as alemtuzumab-based were not allowed. All patients were given ATG pretransplant; however, ex vivo T-cell depletion was not allowed.
Comorbidities were scored according to the Sorror hematopoietic cell transplantation comorbidity index (HCT-CI). The status of disease pre transplant was evaluated according to the CIBMTR criteria as early-, intermediate-, or advanced-stage disease. 24 HLA typing was based on high-resolution typing of class I and class II HLA antigens. Both 10/10 HLA matched and 9/10 HLA matched were allowed for the analysis. The majority of patients (97% in both groups) had G-CSF mobilized peripheral blood stem-cells (the preferred requested option); however, bone marrow was also allowed. All patients were treated according to protocols that were approved by the institution review board and gave written informed consent for their intended protocol. The current analysis was also approved by the institutional review board.
| Conditioning regimens
The conditioning regimen for SCT was selected based on patient disease and medical condition according to standard institutional criteria.
Dose intensity was defined according to the CIBMTR criteria based on the reversibility and expected duration of cytopenia after SCT, with mild modifications. 25 
| Statistical analysis
Patient characteristics were compared between groups by student ttest for continuous variables, and Chi-square test for categorical variables. The probability of OS was estimated using the Kaplan-Meier method. Relapse and nonrelapse mortality (NRM) rates were estimated using cumulative incidence analysis and considered as competing risks.
In the analysis of the cumulative incidence of GVHD, relapse was considered a competing risk. The effect of various patient and disease categorical variables on survival probabilities was studied with the logrank test. Cumulative incidence rates were compared by Gray test. Abbreviations: MTX, methotrexate; MMF, mycophenolate mofetil; AL, acute leukemia; LPD, lymphoproliferative disease; cMPD, chronic myeloproliferative disease; MAC, myeloablative conditioning; RIC, reduced intensity conditioning; FM, fludarabine melphalan; RTC, reduced toxicity conditioning; SC, stem cell; PBSC, peripheral blood stem cell; HCT-CI, hematopoetic cell transplantation comorbidity index.
including 67 patients given FM) or reduced toxicity (n 5 197, 42%). In all, 314 were given cyclosporine and MTX and 158 cyclosporine and MMF for GVHD prophylaxis. The MMF group included older patients than the MTX group (median age 57 vs. 52 y, respectively, P 5 .002). A lower percentage had MAC (9% vs. 25%, P 5 .005). More patients had a lymphoproliferative disease and less had acute leukemia (P 5 .02).
More patients had advanced disease at SCT (65% vs. 39%, P 5 .001), and more had a high HCT-CI (18% vs. 11%, P 5 .03).
| Engraftment
Four hundred and thirty-two patients engrafted. Thirty-one patients 
| GVHD
The cumulative incidence of acute GVHD grade II-IV was 34% (95% CI, 30-39). The cumulative incidence of acute GVHD grade III-IV was 17% (95% CI, [14] [15] [16] [17] [18] [19] [20] [21] [22] . Table 2 outlines the univariate and multivariate analyses of factors predicting acute GVHD. The cumulative incidence Abbreviations: as in Table 1 ; GVHD, graft versus host disease; HR, hazard ratio; BM, bone marrow.
of acute GVHD grade II-IV was 47% (95% CI, 40-56) and 27% (95% CI, 22-33) after MMF and MTX containing regimens, respectively (Figure 1a, P < .001). The cumulative incidence of acute GVHD grade III-IV was 28% (95% CI, 21-37) and 12% (95% CI, 9-17) (P < 0.001). (Table 2) .
Organ involvement was similar in the two GVHD prophylaxis regimen groups with a trend for more gastrointestinal disease after MMF.
Sixty-five percent of patients who had acute GVHD grade II-IV after CsA/MTX had skin involvement, 31% had liver involvement and 53%
had gastro-intestinal involvement (some patients had more than one organ involved. The rates after CsA/MMF were 54% (P 5 .18), 29%
(P 5 .78), and 69% (P 5 .06), respectively.
The cumulative incidence of chronic GVHD was similar after both prophylaxis regimens at 30% (95% CI, [26] [27] [28] [29] [30] [31] [32] [33] [34] . Multivariate analysis identified male gender and MMF treatment as the only independent factors with hazard ratios of 1.5 (P 5 .03) and 1.9 (P 5 .001), respectively (data not shown).
Nonrelapse mortality (NRM) occurred in 145 patients with a cumulative incidence of 30% (95% CI 26-35) at 5 y after SCT. Sixty-four deaths, cumulative incidence 13% (95% CI 11-17), were of complications occurring in patients actively treated for severe GVHD. These were associated with infection in 11 of 25 (44%) patients in the MTX group compared to 25 of 39 patients in the MMF group (64%, P 5 .11)
. The causes of deaths not associated with GVHD included infection (n 5 25, 50%), multiorgan failure (n 5 5, 10%), VOD of the liver (n 5 4, 8%), pulmonary toxicity including alveolar hemorrhage (n 5 5, 10%), cardiac toxicity (n 5 5, 10%), renal toxicity (n 5 1, 2%), graft failure (n 5 1, 2%), CNS hemorrhage (n 5 2, 4%), suicide (n 5 1, 2%), and second malignancy (n 5 1, 2%) in the MTX group. In the MMF, the causes were infection (n 5 23, 74%, P 5 .03), multiorgan failure (n 5 8, 26%), VOD (n 5 3, 10%) and renal toxicity, graft failure and suicide (1 each, 3% each). In all, infection was a leading or contributing cause in 48%
and 69% of NRM events after MTX and MMF, respectively (P 5 .02). (Table 3) . . When adjusting for patient characteristics, the multivariate analysis showed that advanced disease status at SCT was the most prominent factor predicting for increased relapse mortality, HR 2.3 (P < .001). SCT for chronic myeloproliferative disorders was associated with a lower risk of relapse mortality, HR 0.6 (P 5 0.05). Abbreviations: as in Tables 1 and 2 ; OS, overall survival; NRM, nonrelapse mortality. 
| Outcome
| Outcome by intention to treat
One hundred and one patients were given allogeneic SCT from unrelated donors during the years 2008/2009. During this period, the leading prophylaxis regimen was MMF-based and 90 patients (89%) were given this regimen. During the other periods, 303 patients were given MTX (82%, P < .0001). The two groups were otherwise well matched (Table S1) 
| DISCUSSION
In this study, we explored two different prophylaxis regimens for the prevention of GVHD after allogeneic SCT from unrelated donors. We
show that CsA and MTX are more effective than CsA and MMF in the prevention of GVHD. However, after adjusting for differences in patient characteristics, OS is similar after both regimens in the entire group, with some differences in certain patient subgroups.
There is no well documented best approach for GVHD prophy-
laxis. A recent EBMT-ELN working group consensus recommendation
suggested that the combination of CsA (or tacrolimus) and a short course of MTX is the standard regimen for MAC, while MMF can substitute for MTX after RIC, in particular after the least intensive nonmyeloablative conditioning regimens. 28 These recommendations were partially based on the prevailing practice in Europe. The data on the differential outcomes following these two most commonly used regimens is conflicting. Three relatively small randomized studies (number of participants, 39-89) compared outcomes of SCT after CsA (two studies) [11] [12] [13] or tacrolimus (one study) 14 combined with MTX or MMF.
One study enrolled SCT from unrelated donors, 11 one study from HLA-matched siblings, 12, 13 and one study from both. 14 The conditioning regimen was MAC [11] [12] [13] or various regimens. 14 In all, there was no difference in the total incidence of acute GVHD between the regimens.
However, in one study a higher incidence of acute GVHD grade III-IV was observed after MMF, particularly after SCT from unrelated donors. 14 A meta-analysis of these three regimens (a total of 177 participants) by the Cochrane Collaboration found no differences in the rates of acute or chronic GVHD between the different regimens. 15 However, the number of randomized patients was small and the quality of the evidence was determined as low. Several nonrandomized observational studies were reported. [16] [17] [18] [19] [20] [21] The results of these studies are difficult for interpretations as some are based on small numbers. There is wide variability in the schedule and doses of immune suppression drugs and in the conditioning regimen, donor type and stem cell source.
Outcomes regarding the risk of acute GVHD are conflicting. Some studies showed similar rates, 16, 17 some increased rates after MMF [18] [19] [20] and only one lower rates after MMF. 21 In the largest series of patients treated with tacrolimus/MMF (n 5 414), the rates of acute GVHD grade III-IV was 22% and 37% after sibling and unrelated donor SCT, rates that are significantly higher than expected, and resulted in increased NRM. 19 A meta-analysis of 11 studies including 1076 patients determined that while the risk of acute GVHD was comparable between the regimens, the risk for severe grade III-IV acute GVHD was higher after MMF (RR 1.6). 22 The increased risk for severe GVHD after MMF was limited to unrelated donors and not evident after sibling SCT. There were no enough data to determine the differential outcome between MAC and RIC due to paucity of studies in the RIC setting. However, a recent large CIBMTR study, not included in this meta-analysis, compared outcomes between BM and PBSC transplantation after unrelated donor SCT with RIC. 20 While there were no differences in outcomes between the different stem cell sources, patients
given MMF had an increased rate of GVHD and worse outcome compared to those given MTX, after both BM and PBSC transplantation.
Most studies, including the current study did not find a difference in the rates of chronic GVHD between MTX and MMF.
MMF was associated with faster engraftment in the majority of studies. In this study, the median time to neutrophil and platelet engraftment was shorter by a median of 3 d. In the meta-analysis by
Ram et al., it was shorter by a median of 3.6 d. 22 MMF suppresses activated lymphocytes specifically while MTX may also affect the myeloid lineage. 8 This shorter duration of neutropenia may offer an advantage especially in patients with active infections.
In all, the rate of NRM is a combination of GVHD-related deaths as well as deaths related to organ toxicities and infections. MMF is consistently associated across all studies with less severe mucositis and a more favorable toxicity profile than MTX. However, more NRM events were directly related to infection in patients given MMF both in patients with and without significant GVHD. The allocation of patients in the current study to MMF or MTX was not randomized and thus subjected to bias. Patients with high risk for organ toxicities, such as patients with comorbidities were preferentially allocated to MMF.
Thus, it was not unexpected that NRM was altogether higher after MMF. However, during the years 2008-2009 patients were given MMF by center policy, irrespective of risk. All patients transplanted during these years were assessed as treated with MMF while all patients transplanted during the other periods were assessed as treated with MTX including the small fraction given MMF. This allowed us to minimize the bias and the groups were comparable in patient characteristics. In this intention to treat-like analysis, death associated with GVHD was indeed higher after MMF, but other NRM causes were lower, resulting in similar NRM. Relapse mortality was not different between the regimens in the current as well as other studies, thus, OS was also similar. However, the relative role of deaths associated with GVHD-and non-GVHD-associated deaths may be different according to patient and transplant characteristics. In patients who are at high risk for GVHD, such as patients given MAC or mismatched transplant, the risk of GVHD overcomes the advantage in organ toxicity and MTX may have superior outcome. In contrast, patients with a high comorbidity score or active infections, who are susceptible to organ toxicity and early infectious death, respectively, may benefit more from MMF. However, these cannot be currently used as established recommendations in the absence of a large randomized study.
The schedule of MMF treatment in the prophylaxis regimen has not been well established and there is high variability in the dose and route of treatment among the different studies. We have used the recommended schedule by the EBMT consensus including fixed oral dosing of 1 g twice daily. 29 Oral administration was switched to intravenous in patients with severe mucositis or those unable to take oral medications. We have not used drug level monitoring as this is still experimental for MMF. MPA levels are highly variable among patients under oral administration. 30 MPA levels have been shown to be lower after SCT than in patients after solid organ transplantation. 11 This is possibly related to reduced intestinal absorption or to drug interactions.
Lower exposure has been shown in patients given proton-pump inhibitors 31 or cyclosporine in comparison with tacrolimus. 32 Low levels of MMF have been associated with a higher risk for graft failure, acute GVHD and NRM, while higher doses may be associated with less GVHD. [33] [34] [35] Recently, replacement of MMF with enteric-coated MMF, that is better absorbed and less susceptible to drug interactions, resulted in better prevention of GVHD. 23 The duration of MMF treatment may also have a role in particular after RIC when GVHD may appear later. 36 There are also several dose schedules for MTX. While, the standard includes four doses on days 1, 3, 6, and 11, some centers, including our center, have omitted the day 11 dose. 7, 28 This expected theoretically to reduce toxicity but also efficacy of the MTX regimen.
In all, some of the differences between MTX and MMF regimens may be related to different dose and route schedules.
This study has several limitations. Although the donor source was unrelated donors and the vast majority were of PBSC, there was a wide heterogeneity of disease type and status at SCT and conditioning regimens that can influence outcome. GVHD was diagnosed based on clinical grounds. In particular, some of MMF side effects, such as abdominal pain and diarrhea may be confused with intestinal GVHD.
Our observations were limited to CsA combined with MTX and MMF and may not be related to newer regimens such as those combining tacrolimus, sirolimus, and/or post-transplantation cyclophosphamide.
In conclusion, CsA and MTX is more effective regimen than CsA and MMF for GVHD prophylaxis after allogeneic SCT from unrelated donors. This regimen is preferred in patients with a standard risk for NRM having myeloablative conditioning. However, the optimal regimen for a specific patient may depend on the conditioning regimen, degree of matching, disease status, prior therapy and complications, comorbidities and transplant center preference.
